A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

NCT02069041 ↗

Phase 1 Completed 8 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.

Timeline

Start: 2014-04
Primary completion: 2016-09
Completion: 2016-09

Publications

Lin CC, Yang TS, Yen CJ, Cheng R, Liu J, Hsu C. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist. 2020 Dec;25(12):e1921-e1929. doi: 10.1002/onco.13550. Epub 2020 Oct 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Leucovorin	Small molecule	200 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	600 mg/m2	Intravenous

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Summary

Timeline

Publications

Drugs

Indications